J Gen Virol Try Microbiology Online
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Gen Virol 78 (1997), 39-43
© 1997 Society for General Microbiology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Markland, W.
Right arrow Articles by Chambers, S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Markland, W.
Right arrow Articles by Chambers, S. P.
Agricola
Right arrow Articles by Markland, W.
Right arrow Articles by Chambers, S. P.

Journal of General Virology, Vol 78, 39-43, Copyright © 1997 by Society for General Microbiology

ARTICLES

Purification and characterization of the NS3 serine protease domain of hepatitis C virus expressed in Saccharomyces cerevisiae

W Markland, RA Petrillo, M Fitzgibbon, T Fox, R McCarrick, T McQuaid, JR Fulghum, W Chen, MA Fleming, JA Thomson and SP Chambers
Vertex Pharmaceuticals Inc., Cambridge, MA 02139-4242, USA.

cDNA encoding the putative core of the hepatitis C virus NS3 serine protease domain (residues 1-181 of NS3; NS3 (181)) was expressed as an N-terminally (His)6-tagged fusion protein in Saccharomyces cerevisiae. NS3 (181) protease activity was found in soluble cell lysates, and the N-terminal metal-chelating domain facilitated the efficient purification of active enzyme, using immobilized metal affinity chromatography. The purified NS3(181), protease activity was characterized by assaying the trans-cleavage of in vitro transcription- translation generated substrates, and subsequently a previously unobserved cleavage site within the NS5A region was identified. The inhibitory effect of known protease inhibitors was also examined. It is hoped that availability of this method for the expression and purification of the NS3(181) protease will facilitate the development of anti-hepatitis C therapies.


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
R. B. Perni, S. J. Almquist, R. A. Byrn, G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, K. Dinehart, C. A. Gates, S. L. Harbeson, et al.
Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease
Antimicrob. Agents Chemother., March 1, 2006; 50(3): 899 - 909.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. Zhang, Z. Cai, Y.-C. Kim, R. Kumar, F. Yuan, P.-Y. Shi, C. Kao, and G. Luo
Stimulation of Hepatitis C Virus (HCV) Nonstructural Protein 3 (NS3) Helicase Activity by the NS3 Protease Domain and by HCV RNA-Dependent RNA Polymerase
J. Virol., July 15, 2005; 79(14): 8687 - 8697.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. Sarrazin, E. Herrmann, K. Bruch, and S. Zeuzem
Hepatitis C Virus Nonstructural 5A Protein and Interferon Resistance: a New Model for Testing the Reliability of Mutational Analyses
J. Virol., October 2, 2002; 76(21): 11079 - 11090.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
K Nagayama, N Enomoto, N Izumi, M Kurosaki, Y Miyasaka, H Watanabe, J Itakura, C-H Chen, J Tazawa, Y Hoshino, et al.
Sequences in the NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients
Gut, June 1, 2001; 48(6): 830 - 835.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 1997 by the Society for General Microbiology.